Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05780424 · ClinicalTrials.gov registry record · Phase 3
BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 353
- Enrollment target
NCT05780424 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 353 participants.
The verdict
NCT05780424, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 353 participants
- Enrollment target
Study Summary
This study looks at the safety and effectiveness of BRII-196/BRII-198 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either BRII-196/BRII-198 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H3.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Remdesivir
- BIOLOGICAL BRII-196
- BIOLOGICAL BRII-198
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2020-12-16 |
| Est. Completion | 2022-10-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05780424
The ClinicalTrials.gov registry entry for NCT05780424 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05780424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05780424 about?
NCT05780424 is a clinical study titled "BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)". This study looks at the safety and effectiveness of BRII-196/BRII-198 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either BRII-196/BRII-198 plus current standard of care (SOC), or with placebo plus current SOC. This is A...
What is the current status of trial NCT05780424?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 353 participants. The study started on 2020-12-16. Estimated completion is 2022-10-10.
What interventions are being tested in trial NCT05780424?
The interventions under investigation include: Placebo (BIOLOGICAL), Remdesivir (BIOLOGICAL), BRII-196 (BIOLOGICAL), BRII-198 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05780424?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.